|
🐜
|
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
42 auth.
J. Seow,
C. Graham,
B. Merrick,
S. Acors,
S. Pickering,
K. Steel,
O. Hemmings,
Aoife M. O’Byrne,
N. Kouphou,
R. Galão,
G. Betancor,
H. Wilson,
A. Signell,
H. Winstone,
C. Kerridge,
...
I. Huettner,
Jose M. Jimenez-Guardeño,
M. Lista,
Nigel J. Temperton,
L. Snell,
K. Bisnauthsing,
A. Moore,
A. Green,
L. Martinez,
B. Stokes,
J. Honey,
A. Izquierdo-Barras,
G. Arbane,
A. Patel,
M. Tan,
L. O'Connell,
Geraldine O'Hara,
E. Macmahon,
S. Douthwaite,
G. Nebbia,
R. Batra,
R. Martinez-Nunez,
M. Shankar-Hari,
J. Edgeworth,
S. Neil,
M. Malim,
K. Doores
|
10 |
2020 |
10
🐜
|
|
🐜
|
Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant
29 auth.
C. Graham,
J. Seow,
I. Huettner,
H. Khan,
N. Kouphou,
S. Acors,
H. Winstone,
S. Pickering,
R. Galão,
L. Dupont,
M. Lista,
Jose M. Jimenez-Guardeño,
Adam G. Laing,
Yin Wu,
Magdalene Joseph,
...
L. Muir,
M. V. van Gils,
Weng M. Ng,
Helen M. E. Duyvesteyn,
Yuguang Zhao,
T. Bowden,
M. Shankar-Hari,
Annachiara Rosa,
P. Cherepanov,
Laura E. McCoy,
A. Hayday,
S. Neil,
M. Malim,
K. Doores
|
6 |
2021 |
6
🐜
|
|
🐜
|
Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
32 auth.
L. Dupont,
L. Snell,
C. Graham,
J. Seow,
B. Merrick,
T. Lechmere,
T. Maguire,
Sadie R. Hallett,
S. Pickering,
T. Charalampous,
A. Alcolea-Medina,
I. Huettner,
Jose M. Jimenez-Guardeño,
S. Acors,
Nathalia Almeida,
...
D. Cox,
Ruth E Dickenson,
R. Galão,
N. Kouphou,
M. Lista,
A. M. Ortega-Prieto,
H. Wilson,
H. Winstone,
C. Fairhead,
Jia Su,
G. Nebbia,
R. Batra,
S. Neil,
M. Shankar-Hari,
J. Edgeworth,
M. Malim,
K. Doores
|
6 |
2021 |
6
🐜
|
|
🐜
|
SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies
21 auth.
C. Fielding,
P. Sabberwal,
J. Williamson,
Edward J. D. Greenwood,
Thomas W M Crozier,
W. Zelek,
J. Seow,
C. Graham,
I. Huettner,
J. Edgeworth,
...
D. Price,
Paul B Morgan,
K. Ladell,
M. Eberl,
I. Humphreys,
B. Merrick,
K. Doores,
Sam J. Wilson,
P. Lehner,
E. Wang,
R. Stanton
|
5 |
2022 |
5
🐜
|
|
🐜
|
A neutralizing epitope on the SD1 domain of SARS-CoV-2 spike targeted following infection and vaccination
13 auth.
J. Seow,
H. Khan,
Annachiara Rosa,
Valeria Calvaresi,
C. Graham,
S. Pickering,
V. E. Pye,
N. Cronin,
I. Huettner,
M. Malim,
...
Argyris Politis,
P. Cherepanov,
K. Doores
|
5 |
2022 |
5
🐜
|
|
🐜
|
Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike
27 auth.
C. Graham,
J. Seow,
I. Huettner,
H. Khan,
N. Kouphou,
S. Acors,
H. Winstone,
S. Pickering,
R. Galão,
M. Lista,
Jose M. Jimenez-Guardeño,
Adam G. Laing,
Yin Wu,
Magdalene Joseph,
L. Muir,
...
Weng M. Ng,
Helen M. E. Duyvesteyn,
Yuguang Zhao,
T. Bowden,
M. Shankar-Hari,
Annachiara Rosa,
P. Cherepanov,
Laura E. McCoy,
A. Hayday,
S. Neil,
M. Malim,
K. Doores
|
5 |
2021 |
5
🐜
|
|
🐜
|
ACE2 expression in adipose tissue is associated with cardio-metabolic risk factors and cell type composition—implications for COVID-19
36 auth.
J. E. El-sayed Moustafa,
A. Jackson,
Sarah M. Brotman,
Li Guan,
Sergio Villicaña,
A. Roberts,
Antonino Zito,
L. Bonnycastle,
M. Erdos,
Narisu Narisu,
H. Stringham,
Ryan Welch,
T. Yan,
T. Lakka,
Stephen Parker,
...
J. Tuomilehto,
J. Seow,
C. Graham,
I. Huettner,
S. Acors,
N. Kouphou,
S. Wadge,
E. Duncan,
C. Steves,
K. Doores,
M. Malim,
F. Collins,
P. Pajukanta,
M. Boehnke,
H. Koistinen,
M. Laakso,
M. Falchi,
J. Bell,
L. Scott,
K. Mohlke,
K. Small
|
4 |
2022 |
4
🐜
|
|
🐜
|
ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants
18 auth.
J. Seow,
C. Graham,
Sadie R. Hallett,
T. Lechmere,
T. Maguire,
I. Huettner,
D. Cox,
H. Khan,
S. Pickering,
R. Roberts,
...
A. Waters,
Christopher C. Ward,
C. Mant,
M. Pitcher,
Johnston J. Spencer,
J. Fox,
M. Malim,
K. Doores
|
3 |
2022 |
3
🐜
|
|
🐜
|
ADNKA overcomes SARS-CoV2-mediated NK cell inhibition through non-spike antibodies
21 auth.
C. Fielding,
P. Sabberwal,
J. Williamson,
Ejd Greenwood,
Twm Crozier,
W. Zelek,
J. Seow,
C. Graham,
I. Huettner,
J. Edgeworth,
...
D. Price,
B. Morgan,
K. Ladell,
M. Eberl,
I. Humphreys,
B. Merrick,
K. Doores,
Sj Wilson,
P. Lehner,
E. Wang,
R. Stanton
|
3 |
2021 |
3
🐜
|
|
🐜
|
The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern
16 auth.
C. Graham,
T. Lechmere,
Aisha Rehman,
J. Seow,
Ashwini Kurshan,
I. Huettner,
T. Maguire,
Jerry C H Tam,
D. Cox,
Christopher C. Ward,
...
Mariusz Racz,
A. Waters,
C. Mant,
M. Malim,
J. Fox,
K. Doores
|
3 |
2022 |
3
🐜
|
